Esophageal Squamous Cell Carcinoma Resectable
Conditions
Keywords
Esophageal Squamous Cell Carcinoma, neoadjuvant therapy, Nimotuzumab
Brief summary
A higher percentage of radical resection is reported in studies using neoadjuvant chemotherapy followed by surgery versus surgery alone for esophageal cancer. And neoadjuvant chemotherapy may improve overall survival after surgical resection. Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). The concurrent trial is a clinical phase II trial designed to assess the efficacy of the combination of Nimotuzumab administered concurrently with neoadjuvant chemotherapy in patients with resectable Esophageal Squamous Cell Carcinoma, and to further investigate its side-effect and toxicity
Detailed description
A surgical resection is currently the preferred treatment for esophageal cancer if the tumor is considered to be resectable without evidence of distant metastases. A higher percentage of radical resection is reported in studies using neoadjuvant chemotherapy followed by surgery versus surgery alone. The neoadjuvant chemotherapy may improve overall survival. Neoadjuvant chemotherapy with administrations of paclitaxel combined with cisplatin or carboplatin has shown effectively. Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). The clinical phase I study of the combination of Nimotuzumab administered concurrently with chemo-irradiation in patients with local advanced esophageal squamous cell carcinoma has shown the safety and the potential efficacy of Nimotuzumab. The concurrent trial is a clinical phase II trial designed to assess the efficacy of the combination of Nimotuzumab administered concurrently with neoadjuvant chemotherapy in patients with resectable Esophageal Squamous Cell Carcinoma, and to further investigate its side-effect and toxicity.
Interventions
DRUGNimotuzumab combined with paclitaxel and cisplatin
Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36). Cisplatin: 75mg/m2,IV on days 1，22 paclitaxel: 90mg/m2, IV on days 1,8,22,29. patients will receive radical operation 4-6 weeks after Neoadjuvant therapy.
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Histological or cytologic diagnosis of Esophageal squamous cell carcinoma * ECOG performance status 0-2 * Age:18-70 years * Joined the study voluntarily and signed informed consent form * Patients must not have received any prior anticancer therapy * Resectable disease, Stage IIA-IIIC, T2N0M0-T3N1M0（AJCC 2009） * Target lesions can be measured according to RECIST criteria * No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L, TBIL\<1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN * Use of an effective contraceptive for adults to prevent pregnancy * Life expectancy of more than 3 months
Exclusion criteria
* Not suitable to surgery * cervical Esophageal Carcinoma(distance of incisor tooth\<19cm) * early Esophageal Carcinoma(Stage I) * complete esophageal obstruction，Esophageal perforation or hematemesis * other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ * pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives * Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior 11、 History of serious allergic or castor oil allergy 12、 Patients who are not suitable to participate in the trial according to researchers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathology complete remission rate | 1 year | Pathology complete remission rate is the primary outcome measure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| R0 resection rate | 1 year | — |
| objective response rate | 1 year | Objective response rate of neoadjuvant chemotherapy will be assessed. |
| overall survival | 5 years | — |
| tolerability and safety | 2 years | number of adverse events such as leucopenia ,rash,diarrhea and so on |
| Quality of life | 5 years | Quality of life of patients will be evaluated during and after therapy. |
Countries
China
Contacts
Primary ContactYun Fan, Doctor
Outcome results
None listed